In vitro activity of PD 127,391, an enhanced-spectrum quinolone
about
Mechanism of differential activities of ofloxacin enantiomersA critical review of the fluoroquinolones: focus on respiratory infectionsIn vitro susceptibility of Mycobacterium avium complex to the new fluoroquinolone sparfloxacin (CI-978; AT-4140) and comparison with ciprofloxacinRandomized, double-blind, multicenter trial comparing clinafloxacin with imipenem as empirical monotherapy for febrile granulocytopenic patients.Fluoroquinolones and tuberculosis.Pharmacokinetics and inflammatory fluid penetration of clinafloxacin.E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens.Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rodsAntipneumococcal activity of BAY 12-8039, a new quinolone, compared with activities of three other quinolones and four oral beta-lactams.In vitro evaluation of WIN 57273, a new broad-spectrum fluoroquinolone.In vitro and in vivo activities of a new quinolone, WIN 57273, possessing potent activity against gram-positive bacteria.In vitro activities of new antimicrobial agents against multiresistant Staphylococcus aureus isolated from septicemic patients during a Belgian national survey from 1983 to 1985.Comparative in vitro and in vivo activities of six new monofluoroquinolone and difluoroquinolone 3-carboxylic acids with a 7-azetidin ring substituent.Treatment of genitourinary tract infections with fluoroquinolones: clinical efficacy in genital infections and adverse effects.WIN 57273, a new fluoroquinolone with enhanced in vitro activity versus gram-positive pathogens.In vitro and in vivo antibacterial activities of E-4868, a new fluoroquinolone with a 7-azetidin ring substituent.Comparative in vitro activities of new quinolones against coryneform bacteria.Comparative in vitro activity of PD 127391, a new fluoroquinolone agent, against susceptible and resistant clinical isolates of gram-positive cocciComparative in vitro activities of teicoplanin, daptomycin, ramoplanin, vancomycin, and PD127,391 against blood isolates of gram-positive cocciThe mode of action of quinolones: the paradox in activity of low and high concentrations and activity in the anaerobic environment.In vitro and in vivo antibacterial activities of E-4497, a new 3-amine-3-methyl-azetidinyl tricyclic fluoroquinolone.Impact of pH and cationic supplementation on in vitro postantibiotic effectTopical ofloxacin compared with gentamicin in the treatment of external ocular infection. Ofloxacin Study Group.Developments in quinolones. Bacteriology, pharmacokinetics and initial clinical experience of several investigational quinolone derivatives.Clinafloxacin for Treatment of Burkholderia cenocepacia Infection in a Cystic Fibrosis Patient.New and future antibiotics in the treatment of acute respiratory tract infections.The concentrations of clinafloxacin in alveolar macrophages, epithelial lining fluid, bronchial mucosa and serum after administration of single 200 mg oral doses to patients undergoing fibre-optic bronchoscopy.In vitro activity of PD 117596-2, a broad-spectrum difluoroquinolone.Value of new quinolones in the treatment and prophylaxis of infectious diseases: introductory remarks.
P2860
Q24675769-16191822-15F0-451A-B830-1C4ED2EA37E9Q28215446-B021C79A-3F74-4774-810B-9D950493470EQ28328860-39A52677-44D2-44A3-91AC-69EE882D8258Q31918096-867B790D-4E77-4E6A-AEF0-C5D17F3E246AQ34519143-F98451EA-8410-4A02-8DCE-E79E6F75785CQ34746644-A8F21D06-C7E3-4EA2-98CD-324016DC9115Q35111654-E8555F97-D24C-45C2-BEF2-E2B4C425F8DCQ35137076-DC0297E4-7654-4457-B1E7-8651BC20D495Q35139557-E0C4AB13-B987-45BE-BCF3-09232FFFA887Q35248737-8AF957F3-E9A4-40C8-888F-DB564B7DCDBAQ35251994-C4BB21CE-8916-46D7-AFFF-783785150771Q35283050-AE215D38-49E9-4D6E-A992-DE1EA41E03A1Q35284580-6F0B232B-A49F-46A3-AA83-8EECA4B93AA7Q35353461-8F266709-DA4C-480C-A411-CC94B20CCDF3Q35565226-339BAEFE-B46A-4463-8B95-3C1205EEE5F4Q35812502-93A84CB0-1125-49B7-A6CB-6EE09F9FEB5FQ35821977-2818A431-7110-446A-B630-7DB65589E92DQ35862887-CE72561C-7A5E-4543-BAFB-109BD0C9C134Q35885570-9189C269-D8CC-431B-9322-4B18C1B90D5BQ36670132-49E267C9-03AC-4655-82B2-8CEDE80753A0Q36753046-A708BD1A-39F7-4257-866F-76493F029BC6Q36757560-38E66385-8287-4218-8D33-B07F3A03C2A7Q37299512-50A43BC0-8FFE-4F66-BFAA-04FFFC4D1906Q38635746-FA2FFCA9-DCB5-4CCB-8CC4-F52B7E170E6EQ40153492-1F9A5559-0336-4F43-BFC0-CEF1F0EE9FE6Q42572513-1F916079-15CD-4664-AE18-D3165AC39090Q44646640-94A3750E-CD24-4378-9F5B-EE7223EF0721Q54350857-42CC4614-00C0-4B0E-972F-146B3E690604Q54722061-3F9F98F9-1080-4156-85CB-1D3662CEED88
P2860
In vitro activity of PD 127,391, an enhanced-spectrum quinolone
description
1988 nî lūn-bûn
@nan
1988 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1988 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
name
In vitro activity of PD 127,391, an enhanced-spectrum quinolone
@ast
In vitro activity of PD 127,391, an enhanced-spectrum quinolone
@en
In vitro activity of PD 127,391, an enhanced-spectrum quinolone
@nl
type
label
In vitro activity of PD 127,391, an enhanced-spectrum quinolone
@ast
In vitro activity of PD 127,391, an enhanced-spectrum quinolone
@en
In vitro activity of PD 127,391, an enhanced-spectrum quinolone
@nl
prefLabel
In vitro activity of PD 127,391, an enhanced-spectrum quinolone
@ast
In vitro activity of PD 127,391, an enhanced-spectrum quinolone
@en
In vitro activity of PD 127,391, an enhanced-spectrum quinolone
@nl
P2093
P2860
P356
P1476
In vitro activity of PD 127,391, an enhanced-spectrum quinolone
@en
P2093
P2860
P304
P356
10.1128/AAC.32.8.1251
P407
P577
1988-08-01T00:00:00Z